BNTX BioNTech SE

Nasdaq biontech.de


$ 102.67 $ 0.05 (0.04 %)    

Monday, 03-Nov-2025 18:47:23 EST
QQQ $ 622.30 $ 0.00 (0 %)
DIA $ 469.19 $ 0.00 (0 %)
SPY $ 675.00 $ 0.00 (0 %)
TLT $ 89.94 $ 0.00 (0 %)
GLD $ 367.31 $ 0.00 (0 %)
$ 103.955
$ 104.97
$ 102.48 x 1
$ 103.20 x 235
-- - --
$ 81.20 - $ 129.27
879,873
na
24.95M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biontech-sees-higher-2025-sales-driven-by-bristol-myers-partnership

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost...

 biontech-raises-fy2025-sales-guidance-from-1787b-2314b-to-3040b-3274b

BioNTech (NASDAQ:BNTX) raises FY2025 sales outlook from $1.787 billion-$2.314 billion to $3.040 billion-$3.274 billion.

 biontech-q3-eps-014-misses-075-estimate-sales-1776b-beat-1190b-estimate

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $0.75 by 1...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...

 jp-morgan-maintains-neutral-on-biontech-lowers-price-target-to-120

JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $121 to $120.

Core News & Articles

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherap...

 morgan-stanley-maintains-overweight-on-biontech-lowers-price-target-to-131

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $13...

Core News & Articles

https://www.nature.com/articles/d41586-025-03093-6

 jp-morgan-maintains-neutral-on-biontech-raises-price-target-to-121

JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Neutral and raises the price target from $116 to $121.

Core News & Articles

- Reuters 

Core News & Articles

- Reuters

 moderna-reports-8-fold-jump-in-antibodies-with-updated-spikevax

Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in h...

 synopsys-chewy-and-the-trade-desk-are-among-top-10-large-cap-losers-last-week-sep-8--sep-12-are-the-others-in-your-portfolio

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biote...

 pfizer-moderna-biontech-stocks-tumble-after-report-of-plan-to-link-covid-vaccines-to-child-deaths

Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump a...

Core News & Articles

- Reuters

Core News & Articles

https://www.washingtonpost.com/health/2025/09/12/covid-vaccine-child-death-cdc/

 pfizer-biontech-roll-out-covid-19-update-that-boosts-antibodies-4-fold-in-high-risk-adults

Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns rep...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION